AMD Clinical Trial
Official title:
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration: An Ancillary Study to the Age-Related Eye Disease Study-2 (AREDS2)
Background:
Age-related macular degeneration (AMD) is the leading cause of blindness in the United
States. Currently, there is no safe way to obtain cells from the eye to study. But
researchers now can turn other types of cells, like skin or blood, into induced pluripotent
stem (iPS) cells. These can be grown in a lab and turned into other types of cells, like
cells from the eye. This will allow researchers to understand and treat diseases of the eye
such as AMD.
Objectives:
To establish a bank of samples that can be changed into other cell types, such as eye cells,
to better understand diseases such as AMD. Also to test drugs in order to treat various eye
diseases.
Eligibility:
People who provided DNA samples in another protocol (07-EI-0025)
Design:
Participants will be screened with their data from the previous protocol. Participants with
select genetic variants will be chosen and contacted via phone.
Participants will have a punch skin biopsy. The skin will be washed. A numbing medication
will be injected. A small piece of skin will be removed with a biopsy tool. The site will be
covered with a dressing. They will receive instructions on how to care for the area. They
will have follow-up visits if needed for clinical care for the area.
Participants may be asked to return if their first sample did not provide enough cells for
the lab.
Participants sample will be developed into eye cells. The cells will be used to understand
diseases and test new drugs.
Objective: This ancillary study will establish a repository of biospecimens to generate
induced pluripotent stem (iPS) cells that can be differentiated into ocular cell types, to be
used for study of molecular mechanisms of and development of treatments for age-related
macular degeneration (AMD). This repository will allow the cells to be used to perform high
throughput drug screens to identify novel potential therapeutic compounds. Although research
involving multiple different ocular cell types from these patients may be performed, the vast
majority of the work will be centered on the retinal pigment epithelium (RPE) and neural
retina. RPE and/or neural retinal cells generated from the iPS cells of participants with AMD
will be used to analyze molecular mechanisms involved in disease initiation and progression.
Study Population: We plan to recruit 100 participants across multiple sites with AMD from the
original cohort of study participants enrolled in the AREDS2 who are returning for a 10 year
in-clinic study visit and have donated DNA in the AREDS2 study. Up to two participants will
be enrolled at NEI. Participants with the highest genetic burden as well as those with rare
variants will be included in the population.
Design: A 520 blood sample will be collected from 350 participants with specific genetic
variants that are identified prior to the start of the study. Up to 60 participants will be
enrolled at NEI. All of these participants were previously enrolled in the AREDS2 protocol
(07-EI-0025) and they are returning for a 10-year in-clinic study visit for further
phenotyping and for assessing the long-term effects of the ARESD2 supplements. Collected
samples will be used to analyze molecular mechanisms involved in disease initiation and
progression. In addition, the iPS cell-derived ocular cells may be used to perform high
throughput (HTP) drug screens aimed at suppressing the molecular phenotypes of the disease
and to identify potential therapeutic agents for these diseases. This study will typically
require only one visit by each participant.
Outcome Measures: The primary outcome is to develop a repository for iPS cells for
investigators involved in vision research. Secondary outcomes include the assessment of
potential therapies for the treatment of age related macular disorder (AMD). There are no
specific participant-based clinical outcomes for this protocol. Participants will, in
general, be seen only once for this protocol, as this is an ancillary study to the main
study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Recruiting |
NCT03893474 -
Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
|
N/A | |
Completed |
NCT00971464 -
Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation
|
Phase 2 | |
Terminated |
NCT00332657 -
Anecortave Acetate Risk Reduction Trial (AART)
|
Phase 3 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT01766596 -
Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)
|
N/A | |
Completed |
NCT03322930 -
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
|
||
Completed |
NCT01778491 -
AMD Phenotype and Genotype Study
|
||
Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
Active, not recruiting |
NCT03845582 -
Phase 3 Study of ALK-001 in Geographic Atrophy
|
Phase 3 | |
Completed |
NCT03367767 -
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
|
||
Terminated |
NCT00333216 -
Anecortave Acetate Risk-Reduction Trial (AART)
|
Phase 3 | |
Completed |
NCT01570790 -
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00346866 -
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
|
Phase 2 | |
Withdrawn |
NCT00726466 -
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
|
Phase 1 | |
Completed |
NCT00306488 -
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
|
Phase 2 | |
Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01632527 -
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A | |
Recruiting |
NCT03675880 -
TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects
|
Phase 1 |